Crispr Up As Focus On Next: gen therapy candidates

Crispr Therapeutics AG

05/12/2023 11:31

** Shares of CRISPR Therapeutics  CRSP.BN   CRSP.O  rise
1.26% to $72.4 in premarket trading
    ** Late Monday, co discontinued its first-gen CAR-T therapy
candidates CTX110 and CTX130 to focus and expand on its next-gen
candidates CTX112 and CTX131
    ** Co says next-gen candidates have the potential to improve
upon the efficacy observed in first-gen therapies in an
early-to-mid-stage trial in Dec 2022     
    ** Brokerage Jefferies says the shift to next-gen CAR-T
programs would delay commercialization of CRSP's CAR-T programs
by only about a year, but  next-gen programs offer substantial
potential to improve upon CRSP's first-gen therapies
    ** The therapies involve the extraction of a type of white
blood cells or T-cells, re-engineering them to attack cancer and
infusing them back in the body
    ** Co had $1.74 bln in cash, cash equivalents and marketable
securities as of Sep 30
    ** Up to Monday's close, stock up 75.9% YTD 

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com;))